Loading
NASDAQHealthcareBiotechnology
Latest quote
$4.90
−$1.095 · -18.27%
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
Previous close
$4.90
−$1.095 · -18.27%
Regular session · ET · Market data may be delayed.
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
Day range
Current $4.90
52-week range
Current $4.90
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
45
Fair Value
Sentiment
73
Bullish
Risk
72
High Risk
Momentum
33
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
Day range
Current $4.90
52-week range
Current $4.90
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | — | 564 USD | — | — |
| Gross profit | — | — | −564 USD | — | — |
| Research and development | 2.62M USD | 3.23M USD | 1.27M USD | 1.95M USD | 8.4M USD |
| Selling, general, and administrative | 5.18M USD | 5.06M USD | 5.62M USD | 8.91M USD | 9.34M USD |
| Operating expenses | 7.8M USD | 8.28M USD | 6.89M USD | 10.86M USD | 19.29M USD |
| Interest income | 149.57K USD | 178.66K USD | 69.78K USD | 63.34K USD | 6.54K USD |
| Depreciation and amortization | 565 USD | 565 USD | 564 USD | 564 USD | 55.11K USD |
| Operating income | −7.8M USD | −8.28M USD | −6.89M USD | −10.86M USD | −19.29M USD |
| Net income | −7.98M USD | −13.2M USD | −7M USD | −12.73M USD | −19.42M USD |
Company facts updated Sep 13, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Feb 6, 2026 | 1:25 | — | — |
Stock split | Aug 7, 2023 | 1:25 | — | — |
Effective Feb 6, 2026
1:25
Effective Aug 7, 2023
1:25
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
